IDEXX Q3 revenue $842M (+8% organic); EPS $2.15 (+13% comparable); updates FY2022 guidance

IDEXX LABORATORIES INC /DE

2022-Q3 EPS reported $5.97 revenue$2,538,756,000

Q3 revenue $842M, +4% reported, +8% organic; CAG Diagnostics recurring revenue +5% reported, +9% organic.
EPS $2.15, +6% reported, +13% comparable; operating margin 29.1%, +100 bps comparable.
Record global premium instrument placements, +10% YoY; installed base +14%.
FY2022 guidance: revenue growth 3.5-4.5% reported, 6.5-7.5% organic; EPS $7.74-$7.98.
Foreign currency headwinds: ~4% revenue impact, ~$0.25 EPS impact for FY2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IDEXX LABORATORIES INC /DE reported the quarter ended September 30, 2022 results: revenue $842 million, EPS $2.15. Guidance reaffirmed.

Period: the quarter ended September 30, 2022
Revenue: $842 million
EPS: $2.15
Guidance: reaffirmed
Result: reported results

Exact text from the filing

The Company reports revenues of $842 million for the third quarter of 2022, a 4% increase as reported and 8% organically, driven by Companion Animal Group ("CAG") Diagnostics recurring revenue growth of 5% reported and 9% organic, building on strong prior year performance.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

IDEXX LABORATORIES INC /DE filing history →

Source: SEC EDGAR

accession 0000950123-22-010618

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.